scholarly journals Re: Mammographic Breast Density and Family History of Breast Cancer

2003 ◽  
Vol 95 (22) ◽  
pp. 1726-1726
Author(s):  
F. Eisinger
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Breast Density ◽  
Mammographic Breast Density ◽  
History Of

Varying Levels of Family History of Breast Cancer in Relation to Mammographic Breast Density (United States)

2006 ◽  
Vol 17 (6) ◽  
pp. 843-850 ◽  
Author(s):  
Anthony B. Crest ◽  
Erin J. Aiello ◽  
Melissa L. Anderson ◽  
Diana S. M. Buist
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Family History ◽  
Breast Density ◽  
Mammographic Breast Density ◽  
History Of

scholarly journals Mammographic Breast Density and Family History of Breast Cancer

2003 ◽  
Vol 95 (7) ◽  
pp. 556-558 ◽  
Author(s):  
E. Ziv ◽  
J. Shepherd ◽  
R. Smith-Bindman ◽  
K. Kerlikowske
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Breast Density ◽  
Mammographic Breast Density ◽  
History Of

scholarly journals Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population

2017 ◽  
Vol 26 (6) ◽  
pp. 938-944 ◽  
Author(s):  
Thomas P. Ahern ◽  
Brian L. Sprague ◽  
Michael C.S. Bissell ◽  
Diana L. Miglioretti ◽  
Diana S.M. Buist ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Family History ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Breast Cancer Screening ◽  
Breast Density ◽  
Cancer Breast ◽  
Screening Population ◽  
History Of

BRCA1 and BRCA2 germline mutation carriers have a lower breast density compared to high risk women without such mutations

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 1517-1517
Author(s):  
P. Sharma ◽  
J. R. Klemp ◽  
B. F. Kimler ◽  
Q. J. Khan ◽  
E. J. Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
High Risk ◽  
Breast Density ◽  
Genetic Factors ◽  
Mammographic Breast Density ◽  
Mutation Status ◽  
High Risk Women ◽  
Mutation Carriers ◽  
Chi Square Analysis

1517 Background: High mammographic breast density, a known risk factor for breast cancer is influenced by both genetic and non genetic factors. It is not clear if there are differences in breast densities between BRCA1/2 mutation carriers and high-risk non carriers. The aim of this study was to compare breast density in high-risk women with and without BRCA1/2 mutation. Methods: Women at high risk for development of breast cancer (based on family history, prior precancerous disease or prior breast cancer) who underwent genetic testing at the University of Kansas Breast Cancer Prevention Center between 1998 and 2005 were identified under an IRB approved protocol. BRCA1/2 full sequencing was performed at Myriad Genetic Laboratories. The earliest digitized mammogram of these subjects was identified from a preexisting mammogram database. All mammograms had to be prior to/at least one year from any chemoprevention intervention. For subjects with prior breast cancer, mammogram of the uninvolved breast was used. Breast density was assessed on the left craniocaudal mammographic view by computer assisted method, Cumulus. Frequencies of categorical variables were assessed using chi-square analysis. Continuous variables were assessed using Mann-Whitney non parametric test. Multiple regression analysis was used to investigate whether differences are due to variables other than mutation status. Results: The study population consisted of 284 high-risk women who underwent BRCA1/2 testing and for whom a mammogram was available. 30 (11%) had BRCA1 and/or 2 deleterious mutation. There was no difference between mutation carriers and non-carriers for BMI, 5 year Gail risk, parity, menopausal status and HRT use. Mutation carriers were younger (median age 42 vs. 46, p=0.020) and more likely to have a positive family history (100% vs. 85%, p=0.020). Older age (p<0.001), higher BMI (p<0.001) and having a BRCA1/2 mutation (p=0.025) were significantly associated with a lower breast density. Conclusion: Among high risk women, possession of a deleterious BRCA1/2 mutation is associated with lower breast density after adjusting for factors known to affect breast density. This suggests that breast density may be governed by genetic factors other than BRCA1/2 mutation status. No significant financial relationships to disclose.

Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer

2008 ◽  
Vol 14 (1) ◽  
pp. 6-12 ◽  
Author(s):  
Trevor J Powles ◽  
Anthony Howell ◽  
D Gareth Evans ◽  
Eugene V Mccloskey ◽  
Sue Ashley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Event ◽  
Family History ◽  
Postmenopausal Women ◽  
Breast Density ◽  
Red Clover ◽  
Mineral Density ◽  
Adverse Event Profile ◽  
Healthy Women ◽  
History Of

Objective To assess the safety and tolerability of a standardized 40 mg red clover isoflavone dietary supplement (Promensil®, Novogen) in women with a family history of breast cancer to evaluate the feasibility of using the supplement for prevention of breast cancer in healthy women. Study design Healthy women aged 35–70 years (n = 401) with at least one first-degree relative with breast cancer received red clover isoflavones or placebo for three years in a randomized, double-blind, placebo-controlled pilot trial. Participants were assessed clinically and blood samples taken for biochemical analysis every six months. In addition, study participants underwent mammography, bone density and transvaginal ultrasound (postmenopausal women only) once per year. Results No significant differences in breast density, endometrial thickness, serum cholesterol, follicle stimulating hormone levels and bone mineral density were detected between those taking red clover isoflavones and placebo. In postmenopausal women, some significant differences in bone marker levels were seen between active and placebo groups, at six months and at 12 months. The adverse event profile was similar across all red clover isoflavone and placebo groups. Conclusion This three-year study supports the growing body of evidence that treatment with red clover isoflavones is safe and well tolerated in healthy women. Supplements containing red clover isoflavones did not adversely affect breast density, skeletal strength or cardiovascular status. In postmenopausal women, endometrial status was not adversely affected. The adverse event profile was similar between red clover isoflavones, and placebo and endocrine status did not differ.

scholarly journals Mammographic Breast Densities among 200 Nigerian Females in Sokoto, North Western Nigeria

2021 ◽  
Vol 3 (7) ◽  
pp. 01-04
Author(s):  
SULE Muhammad Baba ◽  
Shamaki Amina Muhammad ◽  
SA’IDU Sule Ahmed ◽  
SADISU Mohammed Ma’aji ◽  
YUNUSA Garba Haruna ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Screening Mammography ◽  
Mammographic Breast Density ◽  
Caffeine Consumption ◽  
Breast Examination ◽  
Increased Risk ◽  
History Of ◽  
Mammographic Examination ◽  
North Western

Background: Breast density has been reported to be an independent predictor of breast cancer risk. Women with highest mammographic breast density may have four to six fold increased risk of developing cancer. Aim and Objective: This study is aimed at evaluating the various forms of breast densities following screening and diagnostic mammographic examination. Materials and Methods: From December 2010 and November 2012, 200 females had mammographic breast examination. Seventy-seven (77) females had routine screening mammography while 123 had diagnostic mammographic examination in the department with the General Electric (GE) Alpha-RT machine with model number MGF-101(manufactured 2010). All the subjects had to fill a mammographic form consisting of variables like age, sex, occupation, family history of breast cancer, tribe, contraception, parity, and caffeine consumption, history of surgical intervention (lumpectomy, biopsy and/or mastectomy), previous mammography and last child birth. MLO and CC views were done for the breast examination though additional views were occasionally employed. Results: Breast density decreases with increase in age of the female subjects and breast lesions are better detected following mammography on fatty or less dense breast.

scholarly journals Preoperative Breast Magnetic Resonance Imaging Use by Breast Density and Family History of Breast Cancer

2018 ◽  
Vol 27 (8) ◽  
pp. 987-993
Author(s):  
Louise M. Henderson ◽  
Rebecca A. Hubbard ◽  
Weiwei Zhu ◽  
Julie Weiss ◽  
Karen J. Wernli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Family History ◽  
Magnetic Resonance ◽  
Breast Density ◽  
Breast Magnetic Resonance Imaging ◽  
Resonance Imaging ◽  
History Of ◽  
Breast Magnetic Resonance

The effects of hormonal replacement therapy (HRT) on mammographic breast density and abnormal mammograms prompting further investigation.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 8-8
Author(s):  
Liran Barda ◽  
Avinoam Nevler ◽  
Esther L Shabtai ◽  
Mordechai Gutman ◽  
Moshe Shabtai
Keyword(s):  
Breast Cancer ◽  
Breast Density ◽  
Mammographic Breast Density ◽  
Lower Sensitivity ◽  
Grade Scale ◽  
Risk Of Malignancy ◽  
History Of ◽  
Malignant Lesions ◽  
Screening Mammograms ◽  
The Relationship

8 Background: Mammographic density has been associated with higher risk of breast cancer and lower sensitivity. HRT has been implicated with increased density and is also a risk factor. The relationship between HRT, breast density, and mammographic findings requiring investigation has not been fully investigated. We aimed at analyzing this correlation. Methods: 2,758 consecutive, single-center screening mammograms performed during 1 year were analyzed. Mammograms were supplemented by ultrasound. Density was measured by a semiquantitative, 5-grade scale, and grouped into low (1-3) (LDM) and high density (4-5) (HDM). Demographic and obstetric data, personal and family history of breast cancer, and the use of HRT were entered into database. These parameters were correlated with breast density and any abnormality detected. Univariate and multivariate analysis as well as multivariate logistic regression were performed on SAS 9.2. Results: Mean overall age was 48 (SD = 10.8, range 27-78), mean ages of LDM and HDM groups were 59 ± 10.5 and 50.9 ± 9.3 respectively (p = 0.001). Of 2,758 tests, 2,094 (76%) were LDM and 664 (24%) were HDM. 1,962 women (71%) were postmenopausal and 592 (30%) were on HRT. A difference in density between pre- and postmenopausal women was observed (p = 0.0001). HRT was not associated with higher rate of HDM (18%, n = 105/582) vs.15% n = 211/1370 (p = n.s) without HRT. Abnormality was more likely in postmenopausal HRT-less (52% n = 711/1370) vs. (30% n = 226/582) HRT (p = 0.0001) including solid lump (p = 0.0001), tissue irregularity (p = 0.016) and calcifications (p = 0.0005). Menopause was associated with 48% of any finding vs. 41.4% in pre-menopause women (p = 0.0017). 104 malignant lesions were found in 267 with mammographic findings prompting histological assessment. HRT was associated with lower incidence (28%) of malignancy compared to 50% without HRT. Conclusions: HRT was not associated with increased density nor with higher risk of malignancy; moreover, a lower rate of mammographic abnormality was noted. Albeit further studies are required, the results of this study do not support the notion that HRT increases the likelihood of malignancy or affects breast density.

Sign in / Sign up

Export Citation Format

Share Document